| Literature DB >> 31631794 |
Juan C Rueda1,2, Ana M Santos2, Jose-Ignacio Angarita2, Rodrigo B Giraldo2, Eugenia-Lucia Saldarriaga2, Jesús Giovanny Ballesteros Muñoz3, Elías Forero4, Hugo Valencia2, Francisco Somoza2, Daniel Martin-Arsanios2, Elias-Josué Quintero2, Viviana Reyes-Martinez2, Diana Padilla2, Francy M Cuervo2, Ingris Peláez-Ballestas5, Mario H Cardiel6, Paula X Pavía7, John Londono2,3.
Abstract
In 2014, the chikungunya virus reached Colombia for the first time, resulting in a nationwide epidemic. The objective of this study was to describe the demographics and clinical characteristics of suspected chikungunya cases. Chikungunya infection was confirmed by enzyme-linked immunosorbent assay and 548 patients where included in the study. Of these patients, 295 were positive for antibodies against chikungunya (53.8%), and 27.6% (151/295) were symptomatic for chikungunya infection, with a symptomatic:asymptomatic ratio of 1.04:1. Factors associated with infection included low income and low socio-economic strata (odds ratio [OR]: 1.8; 95% confidence interval [CI]: 1.0-3.2, p = 0.003 and OR: 2.1; CI: 1.3-3.4, p = 0.002, respectively). Confirmed symptomatic cases were associated with symmetric arthritis (OR: 11.7; CI: 6.0-23.0, p < 0.001) of ankles (OR: 8.5; CI: 3.5-20.9, p < 0.001), hands (OR: 8.5; CI: 3.5-20.9, p < 0.001), feet (OR: 6.5; CI: 2.8-15.3, p < 0.001), and wrists (OR: 17.3; CI: 2.3-130.5, p < 0.001). Our study showed that poverty is associated with chikungunya infection. Public health strategies to prevent and control chikungunya should focus on poorer communities that are more vulnerable to infection. The rate of asymptomatic infections among confirmed cases was 48.8%. However, those with symptoms displayed a characteristic rheumatic clinical picture, which could help differentiate chikungunya infection from other endemic viral diseases.Entities:
Keywords: Arbovirus; Chikungunya virus; Colombia; Epidemic; South America
Mesh:
Substances:
Year: 2019 PMID: 31631794 PMCID: PMC6819954 DOI: 10.1080/22221751.2019.1678366
Source DB: PubMed Journal: Emerg Microbes Infect ISSN: 2222-1751 Impact factor: 7.163
Demographics in patients with suspected CHIKV infection.
| IgG or IgM for CHIKV | ||||
|---|---|---|---|---|
| OR (CI) | ||||
| Age in years (mean ± SD) | 49.6 ± 17.4 | 48.9 ± 17.6 | ||
| Female | 208 (54.5%) | 174 (45.5%) | ||
| Mestizo ( | 145 (49.7%) | 147 (50.3%) | ||
| Caucasian ( | 110 (58.5%) | 78 (41.5%) | ||
| Afro-American ( | 29 (70.7%) | 12 (29.3%) | 2.19 (1.09–4.38) | 0.024 |
| Amerindian ( | 8 (33.3%) | 16 (66.7%) | 0.41 (0.17–0.98) | 0.039 |
| Barranquilla ( | 165 (66.5%) | 83 (33.5%) | 2.60 (1.83–3.68) | <0.001 |
| Bogotá ( | 45 (50.0%) | 45 (50.0%) | ||
| Medellín ( | 18 (21.4%) | 66 (78.6%) | 0.18 (0.10–0.32) | <0.001 |
| Cúcuta ( | 36 (65.5%) | 19 (34.5%) | ||
| Bucaramanga ( | 14 (29.8%) | 33 (70.2%) | 0.33 (0.17–0.63) | 0.001 |
| Cali ( | 17 (70.8%) | 7 (29.2%) | ||
| None ( | 107 (53.8%) | 92 (46.2%) | ||
| <157 USD ( | 62 (68.9%) | 28 (31.1%) | 2.13 (1.32–3.46) | 0.002 |
| 158–315 USD ( | 95 (50.3%) | 94 (49.7) | ||
| 316–471 USD ( | 16 (39.0%) | 25 (61.0%) | ||
| 472–630 USD ( | 9 (60.0%) | 6 (40.0%) | ||
| 631–725 USD ( | 2 (66.7%) | 1 (33.3%) | ||
| 726–906 USD ( | 3 (42.9%) | 4 (57.1%) | ||
| >906 USD ( | 1 (25.0%) | 3 (75.0%) | ||
| Stratum 1 ( | 115 (68.0%) | 54 (32.0%) | 2.35 (1.60–3.44) | <0.001 |
| Stratum 2 ( | 104 (46.0%) | 122 (54.0%) | 0.58 (0.41–0.82) | 0.002 |
| Stratum 3 ( | 60 (52.6%) | 54 (47.4%) | ||
| Stratum 4 ( | 9 (28.1%) | 23 (71.9%) | 0.31 (0.14–0.69) | 0.003 |
| Stratum 5 ( | 6 (85.7%) | 1 (14.3%) | ||
CHIKV: chikungunya virus; IgM: immunoglobulin M; IgG: immunoglobulin G; OR: odds ratio; CI: 95% confidence interval; SD: standard deviation, USD: United States dollar.
afulfilled World Health Organization Criteria for confirmed case of CHIKV; bdid not fulfil World Health Organization Criteria for confirmed case of CHIKV.
Figure 1.Profile of the study population. WHO: World Health Organization; CHIKV: chikungunya virus.
Figure 2.Distribution by city according to WHO criteria and CHIKV serology. DANE: Departamento Administrativo Nacional de Estadística; COPCORD: Community Oriented Program for Control of Rheumatic Diseases; WHO: World Health Organization; CHIKV: chikungunya virus.
Joint involvement in patients with suspected CHIKV infection.
| IgG or IgM for CHIKV | ||||
|---|---|---|---|---|
| OR (CI) | ||||
| Symmetric ( | 240 (62.8%) | 142 (37.2%) | 3.41 (2.32–5.00) | <0.001 |
| Hands ( | 158 (68.4%) | 73 (31.6) | 2.84 (1.99–4.05) | <0.001 |
| Wrists ( | 93 (67.9%) | 44 (32.1%) | 2.18 (1.45–3.28) | <0.001 |
| Elbows ( | 74 (66.7%) | 37 (33.3%) | 1.95 (1.26–3.02) | 0.002 |
| Shoulders ( | 81 (56.6%) | 62 (43.4%) | ||
| Knees ( | 184 (62.6%) | 110 (37.4%) | 2.15 (1.53–3.03) | <0.001 |
| Ankles ( | 137 (74.1%) | 48 (25.9%) | 3.70 (2.51–5.46) | <0.001 |
| Feet ( | 104 (67.1%) | 51 (32.9%) | 2.15 (1.46–3.18) | <0.001 |
| Symmetric ( | 90 (93.8%) | 6 (6.3%) | 18.07 (7.74–42.15) | <0.001 |
| Hands ( | 47 (95.9%) | 2 (4.1%) | 23.78 (5.71–98.98) | <0.001 |
| Wrists ( | 19 (95.0%) | 1 (5.0%) | 17.34 (2.30–130.52) | <0.001 |
| Elbows ( | 11 (91.7%) | 1 (8.3%) | 9.76 (1.25–76.13) | 0.008 |
| Shoulders ( | 9 (100.0%) | 0 (0.0%) | ||
| Knees ( | 22 (88.0%) | 3 (12.0%) | 6.71 (1.98–22.71) | <0.001 |
| Ankles ( | 47 (94.0%) | 3 (6.0%) | 15.79 (4.85–51.41) | <0.001 |
| Feet ( | 45 (97.8%) | 1 (2.2%) | 45.36 (6.20–331.61) | <0.001 |
CHIKV: chikungunya virus; IgM: immunoglobulin M; IgG: immunoglobulin G; OR: odds ratio; CI: 95% confidence interval.
afulfilled World Health Organization criteria for confirmed case of CHIKV; bdid not fulfil World Health Organization criteria for confirmed case of CHIKV.
Figure 3.Joint involvement in confirmed CHIKV-infected patients. *p < 0.001.
Dermatological involvement in patients with confirmed CHIKV infection.
| IgG or IgM for CHIKV | ||||
|---|---|---|---|---|
| OR (CI) | ||||
| Face ( | 94 (88.7%) | 12 (11.3%) | 9.39 (5.0–17.62) | <0.001 |
| Thorax ( | 84 (91.3%) | 8 (8.7%) | 12.19 (5.76–25.76) | <0.001 |
| Abdomen ( | 84 (92.3%) | 7 (7.7%) | 13.99 (6.33–30.90) | <0.001 |
| Back ( | 73 (91.3%) | 7 (8.7%) | 11.55 (5.21–25.62.0) | <0.001 |
| Limbs
( | 91 (86.7%) | 14 (13.3%) | 7.61 (4.20–13.77) | <0.001 |
| Presence of pruritus | 87 (86.1%) | 14 (13.9%) | 7.14 (394–12.93) | <0.001 |
| Oral ( | 9 (90.0%) | 1 (10.0%) | ||
| Genital ( | 11 (84.6%) | 2 (15.4%) | 4.86 (1.06–22.14) | 0.024 |
CHIKV: chikungunya virus; IgM: immunoglobulin M; IgG: immunoglobulin G; OR: odds ratio; CI: 95% confidence interval.
afulfilled World Health Organization criteria for confirmed case of CHIKV; bdid not fulfilled World Health Organization criteria for confirmed case of CHIKV.
Gastrointestinal involvement in patients with confirmed CHIKV infection.
| IgG or IgM for CHIKV | ||||
|---|---|---|---|---|
| OR (CI) | ||||
| Diarrhoea ( | 75 (83.3%) | 15 (16.7%) | 5.40 (3.01–9.69) | <0.001 |
| Emesis ( | 33 (82.5%) | 7 (17.5%) | 4.42 (1.92–10.19) | <0.001 |
| Nausea ( | 34 (85.0%) | 6 (15.0%) | 5.36 (2.21–12.99) | <0.001 |
| Abdominal pain ( | 23 (76.7%) | 7 (23.3%) | 2.97 (1.25–7.04) | <0.01 |
CHIKV: chikungunya virus; IgM: immunoglobulin M; IgG: immunoglobulin G; OR: odds ratio; CI: 95% confidence interval; GI: gastrointestinal.
afulfilled World Health Organization criteria for confirmed case of CHIKV; bdid not fulfilled World Health Organization criteria for confirmed case of CHIKV.